New eye drug GB10 enters early human testing for wet AMD
NCT ID NCT07406438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB10 (intravitreal injection)
- What this could lead to
- If successful, this could point toward a new treatment option for wet age-related macular degeneration that may reduce the need for frequent eye injections.
- What could go wrong
- This is a very early Phase 1 trial with only 48 participants, focused on safety and dosing. It is too small and early to know if GB10 will work or be safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730, China
-
Henan Provincial Eye Hospital
Zhengzhou, Henan, 450015, China
-
Nanchang University Second Affiliated Hospital
Nanchang, Jiangxi, 330006, China
-
Sir Run Run Shaw Hospital (SRRSH), affiliated with Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550004, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy tame wet AMD for years?
- Laser zap before eye injection could cut needle count for wet AMD
- New eye injection shows promise for wet AMD in everyday practice
- New syringe could simplify High-Dose eye treatment
- New eye drug faricimab tested for blinding disease
- New eye drug trial aims for safer wet AMD treatment